LncRNA UCA1 in anti-cancer drug resistance

被引：134
|
作者：
Wang, Haohao [1 ,2 ]
Guan, Zhonghai [1 ]
He, Kuifeng [1 ,2 ]
Qian, Jiong [1 ]
Cao, Jiang [3 ]
Teng, Lisong [1 ,2 ]
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Ctr Canc, Hangzhou, Zhejiang, Peoples R China
[2] Key Lab Precis Diag & Treatment Hepatobiliary & P, Hangzhou, Zhejiang, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 2, Coll Med, Clin Res Ctr, Hangzhou, Zhejiang, Peoples R China
来源：
ONCOTARGET | 2017年 / 8卷 / 38期
基金：
中国国家自然科学基金;
关键词：
long non-coding RNA; UCA1; chemoresistance; cancer; LONG NONCODING RNA; CARCINOMA-ASSOCIATED; CHRONIC MYELOID-LEUKEMIA; CELL LUNG-CANCER; ENHANCES TAMOXIFEN RESISTANCE; TYROSINE KINASE INHIBITORS; BREAST-CANCER; MULTIDRUG-RESISTANCE; POOR-PROGNOSIS; MOLECULAR-MECHANISMS;
D O I：
10.18632/oncotarget.18344
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The pivotal role of the long non-coding RNA (lncRNA) urothelial carcinoma associated 1 (UCA1) in anti-cancer drug resistance has been confirmed in many cancers. Overexpression of lncRNA UCA1 correlates with resistance to chemotherapeutics such as cisplatin, gemcitabine, 5-FU, tamoxifen, imatinib and EGFR-TKIs, whereas lncRNA UCA1 knockdown restores drug sensitivity. These studies highlight the potential of lncRNA UCA1 as a diagnostic and prognostic biomarker, and a therapeutic target in malignant tumors. In this review, we address the role of lncRNA UCA1 in anti-cancer drug resistance and discuss its potential in future clinical applications.
引用
收藏
页码：64638 / 64650
页数：13
相关论文
共 50 条
  • [21] LncRNA UCA1 inhibits cell proliferation in coronary heart disease
    Wang, Xiaofeng
    Wang, Yi
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (07): : 6999 - 7003
  • [22] The lncRNA UCA1 promotes proliferation, migration, immune escape and inhibits apoptosis in gastric cancer by sponging anti-tumor miRNAs
    Chao-Jie Wang
    Chun-Chao Zhu
    Jia Xu
    Ming Wang
    Wen-Yi Zhao
    Qiang Liu
    Gang Zhao
    Zi-Zhen Zhang
    Molecular Cancer, 18
  • [23] lncRNA UCA1 Mediates Resistance to Cisplatin by Regulating the miR-143/FOSL2-Signaling Pathway in Ovarian Cancer
    Li, Zewu
    Niu, Huanfu
    Qin, Qianqian
    Yang, Sanhui
    Wang, Qin
    Yu, Chunna
    Wei, Zefeng
    Jin, Zhenzhen
    Wang, Xuenan
    Yang, Aijun
    Chen, Xiaoli
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2019, 17 : 92 - 101
  • [24] The lncRNA UCA1 promotes proliferation, migration, immune escape and inhibits apoptosis in gastric cancer by sponging anti-tumor miRNAs
    Wang, Chao-Jie
    Zhu, Chun-Chao
    Xu, Jia
    Wang, Ming
    Zhao, Wen-Yi
    Liu, Qiang
    Zhao, Gang
    Zhang, Zi-Zhen
    MOLECULAR CANCER, 2019, 18 (1)
  • [25] LncRNA UCA1 promotes vasculogenic mimicry by targeting miR-1-3p in gastric cancer
    Lu, Yida
    Yang, Bo
    Shen, Aolin
    Yu, Kexun
    Ma, MengDi
    Li, Yongxiang
    Wang, Huizhen
    CARCINOGENESIS, 2024, 45 (09) : 658 - 672
  • [26] Extracellular vesicles and anti-cancer drug resistance
    Mc Namee, Niamh
    O'Driscoll, Lorraine
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2018, 1870 (02): : 123 - 136
  • [27] LncRNA UCA1 mediates Cetuximab resistance in Colorectal Cancer via the MiR-495 and HGF/c-MET Pathways
    Yuan, Heng-Heng
    Zhang, Xin-Chen
    Wei, Xiao-Li
    Zhang, Wen-Jie
    Du, Xiao-Xue
    Huang, Peng
    Chen, Hao
    Bai, Lu
    Zhang, Hong-Feng
    Han, Yu
    JOURNAL OF CANCER, 2022, 13 (01): : 253 - 267
  • [28] Signalling Pathways in Anti-cancer Drug Resistance
    Chen, Chen
    Chen, Jiezhong
    Zhao, Kong-Nan
    CURRENT MEDICINAL CHEMISTRY, 2014, 21 (26) : 3007 - 3008
  • [29] Epigenetic reprogramming in anti-cancer drug resistance
    Tan, Jing
    CANCER SCIENCE, 2024, 115 : 402 - 402
  • [30] LncRNA UCA1 regulates cervical cancer surviva and EMT occurrence by targeting miR-155
    Yang, T. -J.
    Wang, L.
    Zhang, Y.
    Zheng, J. -D.
    Liu, L.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (19) : 9869 - 9879
12345